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Prevalence of gestational diabetes mellitus
based on various screening strategies in
western Kenya: a prospective comparison
of point of care diagnostic methods
Sonak D. Pastakia1*, Benson Njuguna2, Beryl Ajwang’ Onyango2, Sierra Washington3, Astrid Christoffersen-Deb4,
Wycliffe K Kosgei5 and Ponnusamy Saravanan6,7
Abstract
Background: Early diagnosis of gestational diabetes mellitus (GDM) is crucial to prevent short term delivery risks
and long term effects such as cardiovascular and metabolic diseases in the mother and infant. Diagnosing GDM
in Sub-Saharan Africa (SSA) however, remains sub-optimal due to associated logistical and cost barriers for
resource-constrained populations. A cost-effective strategy to screen for GDM in such settings are therefore
urgently required. We conducted this study to determine the prevalence of gestational diabetes mellitus (GDM)
and assess utility of various GDM point of care (POC) screening strategies in a resource-constrained setting.
Methods: Eligible women aged ≥18 years, and between 24 and 32 weeks of a singleton pregnancy, prospectively
underwent testing over two days. On day 1, a POC 1-h 50 g glucose challenge test (GCT) and a POC glycated
hemoglobin (HbA1c) was assessed. On day 2, fasting blood glucose, 1-h and 2-h 75 g oral glucose tolerance test
(OGTT) were determined using both venous and POC tests, along with a venous HbA1c. The International Association
of Diabetes in Pregnancy Study Group (IADPSG) criteria was used to diagnose GDM. GDM prevalence was reported
with 95% confidence interval (CI). Specificity, sensitivity, positive predictive value, and negative predictive value of the
various POC testing strategies were determined using IADPSG testing as the standard reference.
Results: Six hundred-sixteen eligible women completed testing procedures. GDM was diagnosed in 18 women, a
prevalence of 2.9% (95% CI, 1.57% - 4.23%). Compared to IADPSG testing, POC IADPSG had a sensitivity and specificity
of 55.6% and 90.6% respectively while that of POC 1-h 50 g GCT (using a diagnostic cut-off of ≥7.2 mmol/L [129.6 mg/
dL]) was 55.6% and 63.9%. All other POC tests assessed showed poor sensitivity.
Conclusions: POC screening strategies though feasible, showed poor sensitivity for GDM detection in our
resource-constrained population of low GDM prevalence. Studies to identify sensitive and specific POC GDM
screening strategies using adverse pregnancy outcomes as end points are required.
Trials registration: Clinical trials.gov: NCT02978807, Registered 29 November 2016.
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Background
Gestational diabetes mellitus (GDM) is associated with
adverse maternal and fetal outcomes which include
macrosomia and subsequent delivery risks such as birth
trauma and increased need for caesarian delivery in the
short term [1, 2]. Long term, mothers with GDM and
their offspring are at an elevated risk for obesity, type 2
diabetes mellitus (T2DM) and other cardiovascular dis-
eases [3–6]. Prompt diagnosis of GDM is the first step
towards effective management and prevention of adverse
outcomes. GDM case detection in Sub-Saharan Africa
(SSA) however, remains sub-standard [7, 8].
The World Health Organization (WHO) adopted
criteria developed by the International Association of
Diabetes and Pregnancy Study Group (IADPSG) in
2013 for the diagnosis of GDM [9, 10]. This approach
however, has certain limitations that limit its applic-
ability in regular diabetes screening in SSA. Firstly, it
requires women to come in fasting for an antenatal
clinic (ANC) visit between weeks 24–28, posing logis-
tical obstacles such as long distance to clinic and asso-
ciated transport costs [11, 12]. Furthermore, women
who aren’t informed during an earlier visit or forget to
come in fasting, require a subsequent visit. Secondly,
quality lab infrastructure and reagents for venous glu-
cose testing are not readily available in most SSA
health facilities and where available, require operation
by skilled and trained personnel who may be unavail-
able [13–16]. Thirdly, multiple samples required for
testing are cumbersome to obtain, both for the woman
and healthcare personnel [15]. Finally, associated costs
for IADPSG testing are high and may be unaffordable
to a majority of low-income patients [14, 17].
Practical and scalable GDM screening and diagnostic
tools are urgently required in SSA [18]. Ideal tools to
overcome the above limitations should be: accurate in
the non-fasting state, avoid need for multiple venous
samples, require minimal training to operate, and be
cost-effective [15]. Point of care (POC) testing devices
possess these characteristics and therefore may be prac-
tical tools for GDM screening in a rural/semi-urban SSA
setting with limited resources and patient follow-up.
Our study evaluated the accuracy of various POC test-
ing modalities for the diagnosis of GDM compared to
the recommended IADPSG testing. We also determined
the prevalence of GDM in a previously unstudied rural/
semi-urban setting of Western Kenya.
Methods
Our prospective study enrolled pregnant women from
any of three ANC clinics namely: the Moi Teaching and
Referral Hospital (MTRH), the Uasin Gishu District
Hospital (UGDH), and Mediheal hospital. MTRH is one
of only two national referral hospitals in Kenya and
serves a varied demography of patients from both rural
and urban Western Kenya. UGDH is a small public
hospital which primarily serves patients from Eldoret
town (semi-urban) and its environs (rural). Mediheal is
a private institution primarily serving patients of higher
income status from urban Eldoret compared to the
other two facilities.
All pregnant women at 24–32 weeks of gestation with
singleton pregnancies were eligible for inclusion. We ex-
tended the gestational age beyond the recommended
24–28 weeks to provide flexibility for women who did not
precisely recall the date of their last normal menstrual
period. Gestational age was confirmed using Naegele’s rule
and compared to the pregnant woman’s fundal height.
Any observed discrepancy of ≥3 weeks was resolved with
evaluation by ultrasound. Women were excluded if they
had a pre-existing diagnosis of diabetes, were less than
18 years old, were on medications that affect glucose con-
trol, or were unable or unwillling to provide informed
consent.
Full approval from the Moi University and MTRH insti-
tutional research ethics committee (approval number –
IREC/2012/66) and the Indiana University-Purdue
University institutional review board were acquired prior
to study initiation. Written informed consent was ob-
tained from all participants. Baseline demographic and
clinical information was obtained for all women using a
structured questionnaire administered on enrollment.
Testing procedures were completed over 2 days. Day 1
tests were conducted on the day of enrollment in a non-
fasting state. A capillary blood sample was obtained to
perform a POC random blood glucose (RBG) test (Optium
H®, Abbott Diabetes Care) and glycated hemoglobin
(HbA1c) (A1C Now®, PTS Diagnostics). An unexpected
stockout necessitated the switch to the desktop DCA Vant-
age (Siemens®) for HbA1c for 76% of the women. A 50 g
glucose load was then administered as a solution from a
commercially available glucose product and capillary blood
samples were collected at 1-h for POC measurement.
All participants were then expected to return the next
day (or within 1 week for those unable to follow-up im-
mediately) after having fasted overnight for ≥8 h. If a
patient had a POC 1-h glucose post-50 g load
≥7.78 mmol/L (140 mg/dL) however, they were notified
that their result met the threshold for a positive screen-
ing and were informed of their need to confirm their
diagnosis on their own if they were unable to come
back for day 2 testing as part of the study.
Day 2 testing procedures included recommended
IADPSG testing alongside the analogous POC tests
(Fig. 1). Capillary and venous blood samples for meas-
urement of POC and venous fasting blood glucose (FBG)
(COBAS® analyzer, Roche Diagnostics), venous HbA1c and
a complete blood count with differential was performed. A
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75 g glucose load was then administered with capillary and
venous blood samples collected at 1-h and 2-h for measure-
ment of POC and venous glucose levels.
All study participants received standard antenatal care
offered at the ANC clinics. Pregnant women who were
diagnosed with GDM using IADPSG criteria were re-
ferred to a home-based glucose monitoring program for
care of GDM [19]. GDM positive mothers were also
called at least 6 weeks after they had delivered to return
to clinic for a fasting blood glucose test to assess
whether they had progressed to diabetes, and provide in-
formation on their delivery.
For fasting, 1-h and 2-h glucose testing following a
75 g oral glucose tolerance test (OGTT), we utilised glucose
cut-offs consistent with IADPSG criteria to define GDM,
[20] that is, venous fasting blood glucose (FBG) >5.1 mmol/
L (92 mg/dL), or 1-h glucose >10 mmol/L (180.0 mg/dL),
or 2-h glucose >8.5 mmol/L (153.0 mg/dL).
We also defined HbA1c values ≥6.5% and
RBG ≥ 11.1 mmol/L (199.8 mg/dL) as meeting criteria for
GDM diagnosis based on their use as cutpoints for overt
diabetes, however, only patients who met IADPSG GDM
diagnostic criteria for the OGTT were informed of having a
GDM diagnosis and were managed as having GDM [20, 21].
The primary outcomes assessed were the prevalence of
GDM determined by IADPSG testing and the sensitivity,
specificity, negative predictive value (NPV) and positive
predictive value (PPV) of different potential screening
strategies when compared to the gold standard 75 g
OGTT venous testing recommended by IADPSG. Second-
ary outcomes includedthe association between POC and
corresponding venous testing results, assessed by calculat-
ing the mean absolute relative difference (MARD), correl-
ation coefficient, and constructing Bland-Altman graphs
for each comparable glucose value. In addition, obstetric
outcomes were assessed by contacting all women diag-
nosed with GDM via phone and completing a standard
data collection form which specifically assessed the pres-
ence of common GDM related complications. All out-
comes were assessed by an independent Obstetrics and
Gynaecology specialist to assess the potential association
with GDM. Every woman was specifically assessed for
fetopelvic disproportion, perineal trauma, preeclampsia,
shoulder dystocia, birth injury for baby, congenital
malformation, neonatal hypoglycemia, and admission
to the neonatal intensive care unit, polycythemia, or
hyperbilirubinemia.
The sensitivity, specificity, NPV and PPV of each
screening strategy was determined using 2 by 2 matrices
with the IADPSG criteria as the gold standard reference.
Based on data from prior trials, we structured our sam-
ple size calculation to identify a screening strategy that
Fig. 1 Study schema and patient flow
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maintained a specificity of 80% and sensitivity of 70% for
the three screening strategies we employed. Prior esti-
mates of GDM in SSA are widely distributed with preva-
lence estimates as low as 0% in some rural regions and
as high as 13.9% among high-risk women in urban areas.
[8] Considering this wide variability, we conservatively
estimated that the prevalence in our semi-urban cohort
would be 7%. Based on this assumption, and anticipating
a 30% loss-to-follow up, we needed to screen 667 preg-
nant women to identify 36 cases with GDM between 24
and 32 weeks gestation for a sensitivity precision of 0.15
and indirectly, a specificity precision of 0.034. Through
the recruitment of 667 women, we would be able to gen-
erate a precise ±2% confidence interval around the esti-
mated GDM prevalence. All analyses were conducted
using Stata Statistical software package (StataCorp, College
Station, TX).
Results and discussion
Results
We exceeded our recruitment target by recruiting 935
eligible pregnant women between July 2013 and August
2015, of whom 886 completed day 1 testing (Fig. 1).
Baseline characteristics for all enrolled women are pre-
sented in Table 1. 250 (28.9%) enrolled participants did
not come back for the day 2 return visit which required
fasting, while 616 (71.1%) completed day 1 and day 2
testing. There were no significant differences in demo-
graphic characteristics between women who only com-
pleted day 1 testing and those who completed both days.
Among women who completed day 1 and day 2 test-
ing, the mean age was 26.1 years and mean gestational
age was 28.3 weeks. 94 (15.3%) reported a family history
of diabetes while 37 (6%) had a systolic and/or diastolic
blood pressure above the cut-off for hypertension diag-
nosis. No patients reported a known history of GDM.
Among women who completed day 1 and day 2 test-
ing, the mean venous fasting glucose was 4 mmol/L
(72.0 mg/dL) and mean venous HbA1c was 5.2%
(33 mmol/mol). Mean values for the 1 h and 2 h venous
glucose were 5.9 mmol/L (106.2 mg/dL) and 5.55 mmol/
L (99.9 mg/dL) respectively. Means for the rest of the
glucose testing procedures are presented in Table 2.
Eighteen women met IADPSG GDM diagnostic cri-
teria, resulting in an overall GDM prevalence of 2.9%
(95% CI, 1.57% - 4.23%) when including only the women
who completed day 1 and day 2 testing in our analysis.
The majority of GDM patients were diagnosed through
a venous FBG whereby 12 of the women met criteria for
venous FBG 5.1 mmol/L (91.8 mg/dL) but not 1 h- or 2-h
75 g OGTT cut-off values. 2-h OGTT venous glucose
≥10 mmol/L (180.0 mg/dL) and 1-h OGTT venous glu-
cose ≥8.5 mmol/L (153.0 mg/dL) solely identified an
additional 3 and 1 patients respectively. The remaining
2 women were positive on all three IADPSG GDM cri-
teria. These 18 GDM positive women had a median
weight of 72.3 kg, median age of 28 years, median gesta-
tional age of 28 weeks, 5.5% (N = 1) with a family history
of diabetes, median systolic blood pressure of 117 mmHg,
and median diastolic blood pressure of 70 mmHg.
Statistical evaluation of the significance of differences
between the GDM positive population and non-GDM
population was limited by the small sample of GDM
positive women.
The sensitivity, specificity, NPV and PPV of the various
screening strategies are shown in Table 3. POC screening
Table 1 Characteristics of women who attended non-fasting and fasting visit
Completed Only Day 1 testing (N = 250) Completed Day 1 and 2 testing (N = 616)
Study Location
MTRH 145 283
UGDH 105 326
Mediheal 0 7
Age (years) (SD) 25.8 (±4.8) 26.1 (±5.1)
Estimated Gestational Age (weeks) (SD) 28.2 (±2.8) 28.3 (±2.6)
Weight (kg) (SD) 61.6 (±10.5) 68.9 (±12.2)
Average SBP (mm/Hg) (SD) 115.8 (±13.5) 112.6 (±18.1)
Average DBP (mm/Hg) (SD) 72.5 (±9.9) 70.8 (±12.9)
SBP ≥ 140 mmHg and/or DBP ≥90 mmHg N(%) 14 (5.6%) 37 (6.0%)
Family history of DM N(%) 38 (15.2%) 94 (15.3%)
Known history of GDM N (%) 0 (0%) 0 (0%)
Average Haemoglobin N/A 12 (±1.5)
Haemoglobin < 8 N (%) N/A 14 (2.3%)
MTRH Moi Teaching and Referral Hospital, UGDH Uasin Gishu District Hospital, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, DM Diabetes mellitus,
GDM Gestational Diabetes Mellitus
Pastakia et al. BMC Pregnancy and Childbirth  (2017) 17:226 Page 4 of 9
Table 2 GDM Prevalence and blood glucose results
Completed Only Day 1 testing (N = 250) Completed Day 1 and 2 testing (N = 616)
Number (%) diagnosed with GDM based on venous 75 g
OGTT IADPSG criteria
18 (2.9%)
Average POC RBG (SD) 4.7 (±1.0) 4.8 (±1.0)
Average POC result after 50 g glucose load (SD) 6.6 (±1.4) 6.9 (±1.4)
Average POC FBG (SD) N/A 4.2 (±0.6)
Average venous FBG (SD) N/A 4.0 (±0.5)
Average POC HbA1c (SD) 5.1 (±0.8) 5.2 (±0.5)
Average venous HbA1c (SD) N/A 5.2 (±0.5)
Average POC 1 h blood glucose post 75 g (SD) N/A 6.9 (±1.4)
Average venous blood glucose 1 h post 75 g (SD) N/A 5.9 (±1.4)
Average POC blood glucose 2 h post 75 g (SD) N/A 6.1 (±1.2)
Average venous blood glucose 2 h post 75 g (SD) N/A 5.5 (±1.1)
MTRH Moi Teaching and Referral Hospital, UGDH Uasin Gishu District Hospital, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, DM Diabetes mellitus,
GDM Gestational Diabetes Mellitus, POC point of care, RBG Random blood glucose, FBG Fasting blood glucose; All blood glucose results presented are in mmol/L,
hemoglobin presented in g/dl
Table 3 Performance of various screening strategies
Sensitivity
TP/(TP + FN)
95% CI
Specificity
TN/(TN + FP)
95% CI
Negative
Predictive Value
TN/(TN + FN)
Negative
likelihood ratio
Point estimate
95% CI
Positive
Predictive Value
TP/(TP + FP)
Positive
likelihood ratio
Point estimate
95% CI
Venous 75 g OGTTa 1
18/(18 + 0)
(0.82–1)
1
598/(598 + 0)
(0.99–1)
1
598/(598 + 0)
n/a 1 (18/18 + 0) n/a
POC RBG ≥ 7 mmol/L
(126.0 mg/dL)
0.17
3/(3 + 15)
(0.06–0.39)
0.97
581/(581 + 17)
(0. 95–98)
0.97
581/(581 + 15)
0.86
(0.70–1.1)
0.15
3/(3 + 17)
5.86
(1.89–18.23)
POC 1 h 50 g ≥ 7.8 mmol/L
(140.4 mg/dL)
0.44
8/(8 + 10)
(0.25–0.66)
0.79
470/(470 + 128)
(0.75–0.82)
0.98
470/(470 + 10)
0.71
(0.47–1.07)
0.06
8/(8 + 128)
2.08
(1.21–3.56)
POC 1 h 50 g ≥ 7.2 mmol/L
(129.6 mg/dL)
0.56
10/(10 + 8)
(0.34–0.75)
0.64
382/(382 + 216)
(0.60–0.67)
0.98
382/(382 + 8)
0.70
(0.41–1.17)
0.04
10/(10 + 216)
1.54
(1.00–2.36)
Venous FBG ≥ 5.1 (91.8 mg/dL) 0.78
14/(14 + 4)
(0.55–0.91)
1
598/(598 + 0)
(.99–1)
0.99
598/(598 + 4)
n/a 1
14/(14 + 0)
0.22
(0.09–0.53)
POC FBG ≥ 5.1 mmol/L
(91.8 mg/dL)
0.33
6/(6 + 12)
(0.16–0.56)
0.95
567/(567 + 31)
(0.93–0.96)
0.98
567/(567 + 12)
0.70
(0.51–0.98)
0.16
6/(6 + 31)
6.43
(3.08–13.45)
POC 75 g OGTT 0.56
10/(10 + 8)
(0.34–0.75)
0.91
542/(542 + 56)
(0.88–0.93)
0.99
542/(542 + 8)
0.49
(0.29–0.82)
0.15
10/(10 + 56)
5.93
(3.66–9.61)
POC HbA1c ≥ 6.5% 0.22
4/(4 + 14)
(0.09–0.45)
0.99
592/(592 + 6)
(0.98–0.99)
0.98
592/(592 + 14)
0.79 (0.61–1.01) 0.4
4/(4 + 6)
22.15 (6.84–71.72)
Venous HbA1c ≥ 6.5% 0.11
2/(2 + 16)
(0.03–0.33)
0.99
591/(591 + 7)
(0.98–0.99)
0.97
591/(591 + 16)
0.90
(0.76–1.06)
0.22
2/(2 + 7)
9.49
(2.12–42.54)
TP true positives, FN false negatives, TN true negatives, FP false positives, HbAIc glycated hemoglobin, OGTT oral glucose tolerance test, POC point of care,
RBG random blood glucose, FBG fasting blood glucose
aAll results were compared to the venous 75 g oral glucose tolerance test to demonstrate diagnostic accuracy
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strategies showed low sensitivity with the POC 75 g
OGTT strategy (‘POC IADPSG’) having the highest sensi-
tivity of 56% and a specificity of 91%. The 1-h post 50 g
glucose load POC had a sensitivity of 44% when utilising a
cut-off of 7.8 mmol/L (140.4 mg/dL) which increased to
56% on adjusting the cut-off to 7.2 mmol/L (129.6 mg/
dL). The specificity of this lower cut-off however dropped
from 79% to 64%. Of the non-POC strategies, venous FBS
was the most accurate with a sensitivity of 77% and
specificity of 100%. When applying the venous HbA1c
diagnostic criteria of ≥6.5%, 10 women were identified
as GDM positive, however only 30% of these women
were positive via the venous 75 g OGTT. The POC
HbA1c also demonstrated limited value for identifying
women who would be positive on the venous 75 g
HbA1c as it was found to have a sensitivity of only 22%
despite having a specificity of 99%.
We found a MARD in the test results between POC
testing and the corresponding venous testing method of
9.3%,19.4%, 16.0%, and 7.7% for fasting, 1-h, 2-h, and
HbA1c testing respectively. The correlation coefficients
and p-values for the fasting, 1-h, 2-h, and HbA1c values
were 0.56 (p < 0.001), 0.72 (p < 0.001), 0.69 (p < 0.001),
and 0.49 (p < 0.001) respectively. Fasting glucose had the
best performance in terms of the MARD despite having
the lowest correlation coefficient of the three. This was
attributed to the larger impact small variations had on
the correlation coefficient at lower glucose values as seen
in the Bland Altman plot of the fasting results (Fig. 2a),
where the y-axis measurements shows a relatively
smaller difference between the two methods of glucose
measurement. The unpredictability of the variability is
also illustrated in Fig. 2a-d, as the results are scattered
above and below zero on all four of the plots illustrat-
ing that POC results could be higher or lower than
venous results.
Among the 18 women who were positive for GDM
based on IADPSG OGTT criteria, 5 (26.3%) were able
and willing to provide details on their delivery and re-
turn for a follow-up fasting glucose at least six weeks
after delivery. None of these women were found to have
diabetes upon repeat screening. An additional 6 (31.6%)
women were contacted only by phone with the remaining
7 (42.1%) women being completely unreachable. The aver-
age birth weight for the 11 women providing data was
3.4 kg with one woman having a macrosomic infant
weighing 4.9 kg without any other complications. An add-
itional 2 women underwent Cesarean delivery with one of
the babies requiring neonatal intensive care unit admis-
sion for an unspecified reason. There was 1 woman who
suffered from an intrauterine fetal death which was
thought to be unrelated to GDM. Perineal trauma was
experienced by 3 additional women without any other
clinical sequelae.
Discussion
We found the prevalence of GDM among pregnant
women receiving care in Western Kenya to be 2.9%. We
used the IADPSG diagnostic criteria to determine preva-
lence, a strategy associated with a 2.4 times higher case
detection compared to older methods [22]. Our low
prevalence may be due to several factors. Firstly, we
employed a universal screening strategy among pregnant
women regardless of pre-existing risk factors. Secondly,
among enrolees, risk factors such as previous GDM, ad-
vanced maternal age and elevated blood pressure were
low, although, family history of DM was reported in 15.3%
of women. Thirdly, our study population represented a
mixed population of urban and rural women. GDM risk
factors in urban populations include overweight and obese
body mass index (BMI), sedentary lifestyle and poor diet-
ary habits. Malnutrition during pregnancy, on the other
hand, may be a risk factor for GDM in rural patients [23].
The majority of our enrollees were recruited from two
public hospitals which predominatly serve a rural popula-
tion from farming communities who are less likely to be
obese and more likely to be active. We therefore posit that
such risk factors were less likely in our study population
although complete socio-economic evaluation and deter-
mination of BMI are required for firm conclusions to be
made.
POC GDM screening strategies performed poorly when
trying to approximate the women who would be GDM
positive based on the venous 75 g OGTT recommended
by IADPSG. The venous 50 g glucose challenge test
(GCT) is extensively used as a screening strategy for
GDM [24]. We conducted a POC version of the 50 g GCT
and found a 56% sensitivity and 64% specificity at a glu-
cose cut-off of ≥7.2 mmol/L (129.6 mg/dL). In contrast,
Coustan and colleagues found that the conventional ven-
ous 50 g GCT at a glucose cut-off of 6.9 mmol/L
(124.2 mg/dL) had a 79% sensitivity and 87% specificity
[25]. The POC version of the 50 g GCT may be used as a
screening test to identify patients who require furthur test-
ing but its low sensitivity limits its utility. A POC 75 g
OGTT strategy had a sensitivity of 56.6% with a specificity
of 90.6%. This method may therefore provide reasonable
accuracy if a POC strategy is required. However, since this
strategy requires for patients to come in fasting, a venous
fasting test alone would be a superior approach despite
the need for venipuncture as this alone had a 77.7% sensi-
tivity and 100% specificity in our study. For field testing in
populations unable to access health facilities regularly
however, the POC 75 g OGTT may be used to identify pa-
tients who requiring further testing.
POC fasting capillary glucose (FCG) testing using a
glucose cut-off of ≥5.1 mmol/L (91.8 mg/dL) in our
study had a very low sensitivity of 33.3%. Fadl and col-
leagues found a slightly higher sensitivity of 47% using
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Fig. 2 Bland Altman Plots of the Venous and POC Testing Strategies Utilized in this Study. a - Fasting Blood Glucose, Venous vs. POC, Correlation
coefficient 0.56, p < 0.001. b - 1 h post 75 g glucose load, Venous vs. POC, correlation coeffiecient = 0.72, p < 0.001. c - 2 h post 75 g glucose
load, Venous vs. POC, correlation coefficient = 0.6910, p < 0.001. d - HbA1c, Venous vs. POC, correlation coefficient = 0.49, p < 0.001
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an FCG cut-off of ≥5 mmol/L (90.0 mg/dL) among a
population at low-risk for GDM [26]. Contralily, Agar-
wal and colleagues reported a sensitivity of 71.9% and
specificity of 76.8% using a FCG cut-off of ≥5.0 mmol/L
(90.0 mg/dL) [27]. Their study however, was conducted
in a setting with a high prevalence (13.4%) of GDM
which may explain the difference in findings.
Additional investigation is required to identify more
accurate POC screening strategies for low-risk GDM
populations such as ours. Capacity for portable field test-
ing is desirable so as to reach pregnant women unable
to access facilities with adequate lab testing resources.
Additionally, future evaluation of a feasible screening
strategy should also incorporate the study of pregnancy
outcomes for all screened women in order to assess the
clinical significance of various glucose cut-offs and testing
strategies within the context of low and middle-income
countries (LMICs). The hyperglycemia and adverse preg-
nancy outcomes (HAPO) study used this approach to
demonstrate that adverse outcomes increase continously
from fasting venous glucose values as low as 4.2 mmol/L
(75.6 mg/dL) [2]. A similar approach in low-resource pop-
ulations not included in the HAPO study may be a more
accurate method of establishing a feasible and clinically
significant screening strategy for GDM. Such an effort
would potentially establish population specific cut-off
points and contextual testing strategies based directly on
pregnancy outcomes within such populations.
Our study has several limitations. Firstly, our low GDM
prevalence limited our ability to evaluate different glucose
cut-off points for POC testing to establish a clinically use-
ful cut-off with good sensitivity and specificity. We in-
creased the sample size to factor in this unexpectedly low
GDM prevalence, we were nevertheless unable to identify
the number of cases necessary to meet our prespecified
threshold. However, based on the limited concordance
found between the various POC strategies tested and the
reference IADPSG criteria, the results of our investigation
are unlikely to change. Secondly, we found considerable
variability between POC test results and corresponding
venous test results. This variability increased when pa-
tients were tested in non-fasting conditions although we
could not find a predictable factor in this variation which
we could use to adjust the POC values. Consequently, this
may have further limited our ability to draw firm conclu-
sions as far as POC screening strategies were concerned.
This study was conducted in a setting that is 2100–
2700 m (7000–9000 ft) above sea level, where the high
altitude may affect the accuracy of POC glucose testing
[28]. Lastly, we were unable to follow up the pregnancy
outcomes for all screened mothers, a strategy that may
more accurately identify glucose cut-off points with sig-
nificant clinical outcomes [2]. Because of this limitation
and the desire to obtain pregnancy outcomes related to
GDM in SSA, we are currently undertaking a larger scale
study where we hope to identify Kenyan specific risk
thresholds related to glucose screening cutpoints as done
within the HAPO study.
Conclusion
We found a low prevalence of GDM (2.9%) in our setting
of Eldoret, Western Kenya. The POC GDM screening
strategies we evaluated, although feasible for the universal
GDM screening of pregnant women in low resource set-
tings, were found to have a low sensitivity in our study
population. Amongst the venous tests evaluated, the ma-
jority of GDM positive patients (77.8%) were identified by
FBG testing. Further investigations are required to identify
accurate POC GDM screening strategies with an emphasis
on adverse pregnancy outcomes as an endpoint.
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